Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Brigitte Lecocq"'
Publikováno v:
Allergy and immunology.
Introduction: STELLAIR1, a real-life retrospective study, demonstrated the efficacy of Omalizumab (OMA) in severe allergic asthma, regardless of blood eosinophil level. The objective of this analysis is to study OMA efficacy in the STELLAR population
Autor:
Raphaël Porcher, Brigitte Lecocq, Muriel Vray, Anne d’Andon, François Bassompierre, Jean-Michel Béhier, Chantal Belorgey, Jacques Bénichou, Gilles Berdeaux, Loic Bergougnoux, Pascal Bilbault, Olivier Chassany, Christian Funck Brentano, Martha Gersberg, Claire Labreveux, Catherine Lassale, Céleste Lebbé, Vincent Lévy, François Montestruc, Caroline Morgan, Gaelle Nachbaur, Brigitte Palestro, Xavier Paoletti, Anne Raison, Laurent Spiess, Nathalie Strub, Christian Vitzling
Publikováno v:
Therapies. 66:309-317
Resume On definit les schemas adaptatifs pour les essais cliniques comme les schemas qui utilisent les donnees accumulees dans l’essai pour en modifier eventuellement certains aspects, sans compromettre la validite et l’integrite de l’essai. Pa
Autor:
Raphaël Porcher, Brigitte Lecocq, Muriel Vray, Anne d’Andon, François Bassompierre, Jean-Michel Béhier, Chantal Belorgey, Jacques Bénichou, Gilles Berdeaux, Loic Bergougnoux, Pascal Bilbault, Olivier Chassany, Christian Funck Brentano, Martha Gersberg, Claire Labreveux, Catherine Lassale, Céleste Lebbé, Vincent Lévy, François Montestruc, Caroline Morgan, Gaelle Nachbaur, Brigitte Palestro, Xavier Paoletti, Anne Raison, Laurent Spiess, Nathalie Strub, Christian Vitzling
Publikováno v:
Therapies. 66:319-326
Adaptive clinical trial designs are defined as designs that use data cumulated during trial to possibly modify certain aspects without compromising the validity and integrity of the said trial. Compared to more traditional trials, in theory, adaptive
Autor:
Jacques Buvat, Barbara Stegmann, Brigitte Lecocq, Dominique Morlier, Detlef Albrecht, Pierre Costa
Publikováno v:
Journal of Urology. 159:116-119
Purpose: We compared the efficacy and safety of alprostadil alpha-cyclodextrin and moxisylyte chlorhydrate to induce erections adequate for sexual intercourse in a prospective, randomized, parallel double-blind study in patients with erectile dysfunc
Publikováno v:
Therapie. 66(4)
Publikováno v:
Therapie. 66(4)
Adaptive clinical trial designs are defined as designs that use data cumulated during trial to possibly modify certain aspects without compromising the validity and integrity of the said trial. Compared to more traditional trials, in theory, adaptive
Autor:
Vincent Lecocq, Antoine Ferry, Marie-Elisabeth Gardin, Michelle Devissaguet, Brigitte Lecocq, Christian Funck-Brentano, Patrice Jaillon
Publikováno v:
Clinical Pharmacology and Therapeutics. 47:397-402
Food has been shown to reduce the bioavailability of the angiotensin-converting enzyme inhibitor captopril, but not the bioavailability of inhibitors administered as ester prodrugs. Perindopril is the ester pro-drug of the angiotensin-converting enzy
Autor:
Alexis Rames, Brigitte Lecocq, Jean-Didier Grangé, Raoul Poupon, Georges Cheymol, Martine Midavaine, Frank LeCoz, Patrice Jaillon, Jean-Marie Poirier
Publikováno v:
Clinical Pharmacology and Therapeutics. 47:354-359
The pharmacokinetics of pentoxifylline were investigated in six healthy volunteers and in 10 patients with alcoholic cirrhosis. After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.
Autor:
Patrice Jaillon, Brigitte Lecocq, Pierre Boisson, Pierre-Louis Prost, Odile Fleurot, Vincent Lecocq
Publikováno v:
The American journal of cardiology. 66(5)
Bepridil is a calcium antagonist that prolongs the duration of ventricular repolarization, whereas CERM 4205, another calcium antagonist, seems to be devoid of any effect on QT interval. The aim of this study was to compare the effects of bepridil an
Autor:
M. O. Richard, O. Vergnoux, Y. Blondel, M. E. Gardin, P. Jaillon, S. Meignan, J. Bergnieres, J. C. Grippat, Brigitte Lecocq
Publikováno v:
Clinical pharmacology and therapeutics. 46(2)
Nalbuphine is a new agonist and antagonist opioid analgesic agent that undergoes an important hepatic metabolism. In this study, we compared the pharmacokinetics of intravenous and oral nalbuphine in three groups of subjects: group I consisted of 14